A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID
(tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid
tumors.
The study will be conducted in 3 parts:
- Part A: MPT-0118 dose-escalation
- Part B: MPT-0118 dose-escalation in combination with pembrolizumab
- Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab